Current glioma classification is based on the 2016 World Health Organization (WHO) guidelines, which differentiates subtypes of gliomas based on the presence or absence of isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion status. This evidence concerns the gene IDH3A and glioma.